HIV-Associated Cardiovascular Disease: A Growing Concern

For decades, human immunodeficiency virus (HIV) was considered primarily an immunological threat. However, with advancements in antiretroviral therapy (ART) dramatically extending the lifespan of individuals living with HIV, a new challenge has emerged: an increased risk of cardiovascular disease (CVD). This article explores the evolving landscape of HIV-associated CVD, its causes, and the implications for patient care.

The Changing Face of HIV Infection

The introduction of ART has transformed HIV infection from a rapidly fatal illness to a manageable, chronic condition. Individuals with HIV are now living longer, and the long-term effects of the virus and its treatment are becoming increasingly apparent. This shift has led to a change in the primary causes of morbidity and mortality among people living with HIV. While opportunistic infections remain a concern, cardiovascular complications are now a leading cause of illness and death ¹.

Prevalence of Cardiac Involvement in HIV

Cardiac involvement in individuals with HIV is surprisingly common. Studies indicate that the prevalence ranges from 28% to 73% ¹. This broad range reflects variations in study populations, diagnostic methods, and the duration of HIV infection and ART exposure.

Understanding HIV-Associated Cardiomyopathy (HIVAC)

HIV-associated cardiomyopathy (HIVAC) is a specific form of heart muscle disease linked to HIV infection. It is classified as a stage IV, HIV-defining illness and continues to contribute significantly to illness and mortality, even in the era of ART ⁴. The causes and how HIVAC manifests depend on the extent of the individual’s immune suppression.

Pathogenesis of HIV-Associated CVD

The development of CVD in people living with HIV is a complex process involving multiple factors. Advances in cardiac imaging and immunology are continually refining our understanding of the underlying mechanisms ². These factors include:

• Direct Viral Effects: HIV can directly infect heart cells, leading to inflammation and damage.
• Chronic Inflammation: HIV infection is characterized by chronic immune activation and inflammation, which contribute to atherosclerosis (plaque buildup in arteries).
• ART-Related Metabolic Complications: Some ART regimens can cause metabolic abnormalities, such as high cholesterol and insulin resistance, increasing CVD risk.
• Traditional CVD Risk Factors: People with HIV often have a higher prevalence of traditional CVD risk factors like hypertension, smoking, and diabetes.

The Long-Term Impact on Cardiovascular Health

As individuals with HIV live longer, the cumulative impact of these factors on cardiovascular health becomes more pronounced. Cardiovascular involvement is now recognized as a significant long-term consequence of HIV infection ³.

Looking Ahead

The increasing prevalence of CVD in people living with HIV underscores the need for comprehensive cardiovascular risk assessment and management in this population. Continued research is crucial to further elucidate the mechanisms driving HIV-associated CVD and to develop targeted prevention and treatment strategies. A proactive approach to cardiovascular health is essential to improve the long-term outcomes for individuals living with HIV.